The near-exclusive expression of RAET1L (ULBP6) in malignant cells within the tumor microenvironment distinguishes it from nontumor-specific NKG2DLs such as MICA/B, which may translate to an improved therapeutic window for ULBP6-targeting therapies. Here, RAET1L is linked to neoplasm.